Aktiesnakken — September 2013
-
den store surprise i år vil være hvis vi får topline fra DAHANCA og de viser noget vildt
-
det står bare i så skarp kontrast til at Jan kalder arzerra blockbuster i autoimmun etc. det koster lidt på hans credit hvis autoimmun droppes i RRMS
-
Vi skal dog huske vi har fået phase III et den lille indikation i år
-
pemphigus vulgaris
-
Hvor stort er det marked?
-
dont jinx it - vi ved jo alle analytikerne følger eksperterne på PI
-
217
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind